How do you factor ctDNA into treatment selection and management? How do you integrate ctDNA with radiographic or pathologic correlates? Are there challenges associated with the interpretation of ctDNA to inform your clinical decision-making? What do we know about sensitivity of ctDNA with different sites of metastatic disease? Navigating positive results Navigating false negatives How do you describe these test results to patients? Do you have any practical insights to share for interpretating and presenting results?